64132K201 Institutional Ownership & Shareholders
NEUBASE THERAPEUTICS INC (64132K201) is currently held by 1 institutional investors tracked by InsiderSet, with a combined reported market value of approximately $100,912 based on the latest available SEC Form 13F filings for the quarter ended December 31, 2023.
Greenlight Capital is currently the largest disclosed institutional shareholder of 64132K201 tracked by InsiderSet, reporting ownership valued at approximately $100,912 in its December 31, 2023 SEC Form 13F filing.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed 64132K201 value among the investors covered in this analysis. Major shareholders include Greenlight Capital, and several other long-term asset managers with concentrated positions in NEUBASE THERAPEUTICS INC (64132K201).
This page ranks the largest institutional 64132K201 shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
Institutional Holders
1
Total Reported Value
$100,912
Largest Holder
Greenlight Capital
Largest Position
$100,912
Insider Transactions (90d)
0
Latest Filing Quarter
Q4 2023
New Institutional Positions
2
Funds Exiting Positions
0
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Greenlight Capital | David Einhorn | 0.00% | 136,350 | $100,912 | — | — | — |
Frequently asked questions about 64132K201
Who are the largest institutional holders of 64132K201?
The largest institutional holders of 64132K201 reported in the latest SEC Form 13F filings include Greenlight Capital. InsiderSet ranks institutional holders by their latest reported 64132K201 position.
What is 64132K201 institutional ownership?
This page tracks 64132K201 positions reported by institutional investment managers through SEC Form 13F. NEUBASE THERAPEUTICS INC (64132K201) institutional ownership on InsiderSet reflects disclosed 13F holdings among the managers we analyze, not every shareholder of the stock.
How many institutions own 64132K201?
InsiderSet currently tracks 1 institutional managers reporting 64132K201 holdings in the latest available 13F data. This count reflects institutions included in the SEC Form 13F filings analyzed by InsiderSet and should not be interpreted as the total number of 64132K201 shareholders.
How much 64132K201 stock do institutions own?
Institutional investment managers disclosed approximately $100,912 in 64132K201 holdings for Q4 2023. This figure is reported 13F value as of the filing period, not necessarily today's market value.
When was 64132K201 institutional ownership last updated?
The latest 64132K201 institutional ownership data on InsiderSet is based on SEC Form 13F filings for the quarter ended December 31, 2023. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time institutional holdings.
Are institutional 64132K201 holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by institutional investment managers as of the end of the reporting quarter. An institution may have changed its 64132K201 position after the reporting date.
Are institutions buying or selling 64132K201?
Institutional buying and selling can be analyzed by comparing 64132K201 positions across consecutive 13F reporting periods. InsiderSet's 64132K201 Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View 64132K201 ownership changes.
How has 64132K201 institutional ownership changed over time?
InsiderSet tracks 64132K201 institutional holdings across multiple 13F reporting periods, allowing investors to compare institutional holder counts, reported value, and reported shares over time.